Literature DB >> 21916989

Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.

Hong Sang Oh1, Dong Ho Lee, Ji Yeon Seo, Yu Ri Cho, Nayoung Kim, Sook Hyang Jeoung, Jin Wook Kim, Jin Hyeok Hwang, Young Soo Park, Sang Hyub Lee, Cheol Min Shin, Hyun Jin Cho, Hyun Chae Jung, In Sung Song.   

Abstract

BACKGROUND AND AIMS: The eradication rate of proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) infection has decreased, mainly due to increasing antibiotic resistance, especially against clarithromycin. It has been reported that a 10-day sequential strategy can produce good outcomes. The aim of this prospective study was to assess the efficacy of sequential therapy as the first-line treatment for the eradication of H. pylori in Korea.
METHODS: A total of 116 patients with proven H. pylori infection received 10-day sequential therapy (20 mg rabeprazole and 1 g amoxicillin, twice daily for the first 5 days, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole, twice daily for the remaining 5 days); 130 patients received 7-day triple therapy (20 mg rabeprazole, 500 mg clarithromycin, and 1 g amoxicillin, twice daily for 7 days). Eradication was evaluated by the (13) C-urea breath test, 4 weeks after the completion of treatment. Compliance and adverse events were assessed.
RESULTS: The eradication rates of 10-day sequential therapy and PPI-based triple therapy were 79.3% (92/116) and 63% (82/130) by intention-to-treat analysis, respectively (P = 0.005), and 81.9% (91/111) and 64.5% (82/127) by per protocol analysis, respectively (P = 0.003). Mild adverse events occurred in both therapy groups (27.5% vs 23.8%), but both treatments were well tolerated.
CONCLUSION: The eradication rate of the 10-day sequential therapy regimen was significantly higher than that of PPI-based triple therapy in the Korean population. Ten-day sequential therapy might be effective as a first-line treatment for H. pylori infection in Korea.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21916989     DOI: 10.1111/j.1440-1746.2011.06922.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

1.  Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 2.  Helicobacter pylori in gastric carcinogenesis.

Authors:  Hyo Jun Ahn; Dong Soo Lee
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

Review 3.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.

Authors:  Vikram Kate; Raja Kalayarasan; Nilakantan Ananthakrishnan
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

4.  Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

Authors:  Hyuk Soon Choi; Hoon Jai Chun; Sang Hoon Park; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon-Tae Jeen; Soon Ho Um; Hong Sik Lee; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

5.  Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.

Authors:  Boram Han; Hyo Jung Kim; Ho-Young Yhim; Doyeun Oh; Sung Hwa Bae; Ho-Jin Shin; Won-Sik Lee; JiHyun Kwon; Jeong-Ok Lee; Hwa Jung Kim; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2022-05-28       Impact factor: 3.673

6.  The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.

Authors:  Tran T Binh; Seiji Shiota; Lam T Nguyen; Dung D Q Ho; Hai H Hoang; Long Ta; Dung T Trinh; Toshio Fujioka; Yoshio Yamaoka
Journal:  J Clin Gastroenterol       Date:  2013-03       Impact factor: 3.062

7.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.

Authors:  Hassan Seddik; Samir Ahid; Tarek El Adioui; Fatim-Zohra El Hamdi; Mohammed Hassar; Redouane Abouqal; Yahia Cherrah; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2013-05-22       Impact factor: 2.953

8.  Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.

Authors:  Ji Hyun Lim; Dong Ho Lee; Seong Tae Lee; Nayoung Kim; Young Soo Park; Cheol Min Shin; In Sung Song
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

Review 9.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

10.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.